Acutaas Chemicals liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
68.14×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.82×3.82×3.91×1.74×2.89×
2.82×2.82×3.02×1.19×2.15×
28921618529.730.5
759650589211307
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ACUTAAS₹3,976.70

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹32,558 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————68.14
Current Ratio2.891.743.913.823.82
Quick Ratio2.151.193.022.822.82
Cash, Equiv & ST Investments30.529.7185.2215.6288.8
Working Capital307.2210.6589.4650.5758.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.